Article Sidebar
Views pdf: 0
EVALUATION OUTCOMES OF NEOADJUVANT GEMCITABINE-CISPLATIN REGIMEN AND CURATIVE SURGERY IN MUSCLE-INVASIVE BLADDER CANCER
Main Article Content
Abstract
Objectives: To evaluate treatment outcomes and associated prognostic factors with survival in patients with muscle-invasive bladder cancer (MIBC) who received neoadjuvant with gemcitabine–cisplatin regimen followed by radical cystectomy at K Hospital. Subjects and Methods: A retrospective study was conducted on 61 patients with MIBC (T2–T4aNxM0) treated at K Hospital from 8/2017-8/2021. Results: The overall response rate after chemotherapy was 81,7%. Pathological complete response after surgery was 25% of cases. The mean overall survival (OS) was 75.8 ± 4.1 months; 3-, 5-, and 7-year OS rates were 84.4%, 76.7%, and 65.9%, respectively. The mean disease-free survival (DFS) was 65.9 ± 4.6 months; 3-, 5-, and 7-year DFS rates were 75.5%, 63.9%, and 60.7%, respectively. Both clinical response after chemotherapy and pathological response after surgery were significantly associated with OS and DFS (p < 0.05). Conclusion: Neoadjuvant gemcitabine–cisplatin combined with radical cystectomy achieved high response rates and improved both DFS and OS in patients with MIBC. Clinical and pathological responses were identified as strong prognostic factors for survival outcomes.
Article Details
Keywords
bladder cancer, gemcitabine-cisplatin, neoadjuvant
References
2. Grossman HB, Natale RB, Tangen CM, et al. (2003), "Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer", N Engl J Med, 349 (9), pp. 859-66.
3. Benkhadra R, Nayfeh T, Patibandla SK, et al. (2022), "Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer", Bladder Cancer, 8 (1), pp. 5-17.
4. Goel S, Sinha RJ, Bhaskar V, et al. (2019), "Role of gemcitabine and cisplatin as neoadjuvant chemotherapy in muscle invasive bladder cancer: Experience over the last decade", Asian J Urol, 6 (3), pp. 222-229.
5. Lyer G, Tully CM, Zabor EC, et al. (2020), "Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience", Clin Genitourin Cancer, 18 (5), pp. 387-394.
6. Pfister C, Gravis G, Flechon A, et al. (2024), "Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study", Lancet Oncol, 25 (2), pp. 255-264.
7. Nabil, R.A., et al. (2024), "Comparison of long-term outcomes between ileal conduit and transuretero-cutaneostomy urinary diversion after radical cystectomy: a systematic review and meta-analysis", Rep Pract Oncol Radiother, 29(1): p. 103-112.
8. Lại Phú Thái Sơn (2020). "Đánh giá kết quả hóa chất bổ trợ trước ung thư bàng quang bằng phác đồ gemcitabine cisplatin Chuyên khoa cấp II, Đại học Y Hà Nội, (2020)."
9. Dash A, Pettus JAt, Herr HW, et al. (2008), "A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience", Cancer, 113 (9), pp. 2471-7.